What is Quantumzyme Corp. (QTZM) stock price today?

Quantumzyme Corp. (QTZM) is currently trading at $0.80, up 33.33% today.

What is QTZM P/E ratio?

Quantumzyme Corp.'s P/E ratio is -6.46. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is QTZM return on equity (ROE)?

Quantumzyme Corp.'s return on equity (ROE) is 997.31%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is Quantumzyme Corp.'s market cap?

Quantumzyme Corp. has a market capitalization of $31.17M.

OTC · Chemicals - Specialty

Quantumzyme Corp. (QTZM) Stock

$0.80 +33.33% OTC: QTZM Basic Materials

Quantumzyme Corp. is a biotransformation firm specializing in the creation of engineered enzymes, primarily utilized for the production of active pharmaceutical ingredients (APIs).

Valuation

Metric	Value
Price	$0.80
Market Cap	$31.17M
P/E Ratio	-6.46
P/B Ratio	-63.76
P/S Ratio	0.00
EPS (TTM)	$-0.01
52-Week High	$5.04
52-Week Low	$0.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	997.31%
ROA	—
ROCE	27.10%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	-0.57
Current Ratio	0.00

Annual Financials (USD)

Metric	2016	2017	2018	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	—	—	—	$0	$0
Net Profit	$0	$0	$0	$0	$0
EPS	$0.00	$-0.01	$-0.01	$-0.01	$-0.01
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2025
Total Assets	$0
Total Liabilities	$0
Cash	$0
Borrowings	$0

Latest News

NVIDIA is Acquiring ‘Dark Fiber’ Across the United States. Here’s Why That’s a Big Deal. 24/7 Wall St. · Jul 23, 2026 First Hawaiian Bank (FHB) Q2 Earnings: What To Expect StockStory · Jul 23, 2026 iQIYI Premieres "Mystic Tales: The Spider Lady's Vendetta", Bringing China's Supernatural Folklore to Life Through AIGC PR Newswire · Jul 23, 2026 CLINUVEL implements strategic reorganisation to refocus on U.S. markets GlobeNewswire · Jul 23, 2026 medmix Strengthens Profitability and Cash Flow While Advancing Growth and Efficiency Initiatives TMX Newsfile · Jul 23, 2026

Cash Flow (USD)

Metric	2025
Operating Cash Flow	$0
Investing Cash Flow	$0
Financing Cash Flow	$0
Net Cash Flow	$0
Free Cash Flow	$0

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-261.59
FCF Yield	-0.20%
Quick Ratio	0.00
Interest Coverage	8.84
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALTO	$5.07	-4.11%	29.06	$393.06M	0.00%
FMST	$1.52	-7.88%	-3.38	$18.92M	0.00%
KBSX	$0.91	+1.11%	-8.87	$40.74M	0.00%
LITMFrontier Nuclear and Minerals Inc.	$2.02	+3.59%	-0.90	$36.41M	0.00%
LOOPLoop Industries, Inc.	$0.78	-2.98%	-3.33	$37.74M	0.00%

About Quantumzyme Corp.

Quantumzyme Corp. is a biotransformation firm specializing in the creation of engineered enzymes, primarily utilized for the production of active pharmaceutical ingredients (APIs). Established in 2015, the company was formerly known as Reliant Services, Inc. until it rebranded as Quantumzyme Corp. in March 2023. Its operations are headquartered in San Diego, California.

Quantumzyme Corp. is headquartered in US.

Quantumzyme Corp. (QTZM) stock trades at $0.80 with a market capitalization of $31.17M. The stock is valued at a price-to-earnings (P/E) ratio of -6.46, price-to-book of -63.76, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $5.04, and currently trades 84.1% below its 52-week high.

On profitability, Quantumzyme Corp. generates a return on equity (ROE) of 997.31% — well above the market average, a sign of a high-quality business, return on capital employed of 27.10%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.quantumzymecorp.com